Similarly, the anti‐tumor effect of EGCG also occurred in parallel with a decrease in FASN levels, which was found to be associated with a decreased level of AKT and ERK1/2 phosphorylation in triple‐negative breast cancer [79]. This evidence concerns the gene FASN and neoplasm.